Log in to your Inderes Free account to see all free content on this page.
Spago Nanomedical
0.12 SEK
-4.23 %
Less than 1K followers
SPAGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-4.23 %
+6.87 %
-1.97 %
+6.87 %
+37.72 %
-4.24 %
-76.71 %
-97.46 %
-98.46 %
Spago Nanomedical is active in biotechnology. The company develops nanomedicine for the diagnosis and treatment of life-threatening diseases. The company's main activities are focused on developing a cancer-selective contrast agent for magnetic resonance imaging (MRI), as well as a product for radionuclide treatment of cancer. Both of these projects are based on proprietary nanomaterials. The largest operations are in the Nordic market, with the headquarters located in Lund.
Read moreMarket cap
82.37M SEK
Turnover
114.41K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
10.6.
2026
General meeting '26
20.8.
2026
Interim report Q2'26
5.11.
2026
Interim report Q3'26
All
Press releases
ShowingAll content types
Spago Nanomedical resolves on a rights issue of approximately SEK 16 million
Spago Nanomedical publishes the annual report for 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio